Sezary症候群（SS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計義大利Sezary症候群市場規模將從 2025 年的 1,600 萬美元成長到 2035 年的 3,800 萬美元。
• 推動市場成長的因素如下：
• 擴大標標靶治療和免疫療法的應用
• 持續研發治療皮膚T細胞淋巴瘤的新療法
• 未來的成長取決於能夠持續控制疾病和改善患者預後的療法。

Sezary症候群（SS）概述

Sezary症候群(SS) 是一種罕見的皮膚T細胞淋巴瘤白血病變異型，其特徵是廣泛的皮膚病變、劇烈瘙癢，且病情進展速度比大多數其他皮膚T細胞淋巴瘤更快，此外，血液中還存在惡性T細胞循環。儘管針對CCR4的抗體藥物mogamulizumab等治療方法改善了預後，但復發仍然很常見，凸顯了開發新療法的必要性。這使得人們對lactamab產生了濃厚的興趣，First-in-Class抗體，KIR3DL2是Sezary症候群細胞上表達的一種受體。該藥物在接受標準治療後病情進展的患者中顯示出良好的療效。由於存在嚴重的安全性問題，該藥物的研發曾一度暫停，但目前臨床評估已恢復，一項評估其作用的註冊試驗正在進行中。對於相關人員，Sezary症候群是罕見疾病領域創新如何從重大的臨床和監管挫折中恢復過來的典型例子。

主要亮點

• 在德國，預計 2025 年至 2035 年間，Sezary症候群(SS) 的新病例數將穩定在 45 例。
• Sezary症候群是一種罕見且高度侵襲性的皮膚 T 細胞淋巴瘤，預後不良。
• 患者往往面臨晚期疾病、免疫功能障礙和治療選擇有限的問題。
• 目前仍迫切需要能夠提供持續療效並提高存活率的治療方法。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Innate Pharma
• SciTech Development, Inc.
• Prescient Therapeutics, Ltd.
• Kyowa Kirin, Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Sezary Syndrome (SS) Market Outlook

Thelansis's "Sezary Syndrome (SS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sezary Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sezary Syndrome (SS) Overview

Sezary syndrome (SS) is the rare leukemic variant of cutaneous T-cell lymphoma, characterized by malignant T cells circulating in the blood alongside widespread skin involvement, severe itching, and a more aggressive course than most other cutaneous T-cell lymphomas. Although therapies such as the CCR4-targeted antibody mogamulizumab have improved outcomes, relapse remains common, highlighting the need for new treatment options. This has driven interest in lacutamab, a first-in-class antibody targeting KIR3DL2, a receptor expressed on most Sezary syndrome cells, which has demonstrated promising activity in patients whose disease progressed after standard therapy. Development was temporarily paused because of a significant safety concern, but clinical evaluation has since resumed, with ongoing registrational studies assessing its role. For stakeholders, Sezary syndrome illustrates how rare-disease innovation can recover from meaningful clinical and regulatory setbacks.

Key Highlights

• In Germany, incident Sezary Syndrome (SS) cases are projected to remain stable at 45 cases between 2025 and 2035.
• Sezary Syndrome is a rare and aggressive leukemic variant of cutaneous T-cell lymphoma with poor prognosis.
• Patients often experience advanced disease, immune dysfunction, and limited treatment options.
• Significant unmet need remains for therapies that provide durable responses and improve survival.

Market Overview

• The Italy Sezary Syndrome market is projected to grow from $16M in 2025 to $38M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted and immunotherapy-based treatments
• Ongoing development of novel therapies for cutaneous T-cell lymphoma
• Future growth will depend on therapies offering durable disease control and improved patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Innate Pharma
• SciTech Development, Inc.
• Prescient Therapeutics, Ltd.
• Kyowa Kirin, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)